Oral mucositis is the most common complication of chemotherapy, and occurs usually in the people suffering from head and neck cancer. It causes damage to mucosal lining of the mouth which results in formation of ulcers and infections. The disease occurs usually occurs after 5 to 10 days of a chemotherapy process in cancer patients. Oral mucositis leads to different problems such as severe pain in mouth, lack of nutrition due to inability to eat, increased risk of infections due to open sores in the oral cavity. The disease usually lasts for one week to six weeks or more.
Due to the COVID-19 pandemic, the global Drugs for Oral Mucositis market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2023-2030. Fully considering the economic change by this health crisis, the Europe Drugs for Oral Mucositis market is estimated at US$ million in 2023, while the United States and China are forecast to reach US$ million and US$ million by 2030, respectively. The proportion of the United States is % in 2023, while Chinese percentage is %, and it is predicted that China market share will reach % in 2030, trailing a CAGR of % through the analysis period. As for the Europe Drugs for Oral Mucositis landscape, Germany is projected to reach US$ million by 2030. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The classification of Oral Mucositis Drugs includes Mouthwash, Pain Control Medication and Other, the sales of Mouthwash are 16.9 million units, with its market share 48.8%. And the sales market share of Pain Control Medication is 38% in 2017.
This report focuses on Drugs for Oral Mucositis volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Drugs for Oral Mucositis market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Drugs for Oral Mucositis Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Mouthwash
Pain Control Medication
Other
Segment by Application
Hospitals
Dental Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
3M Healthcare
GSK
Pfizer
Colgate-Palmolive
Norgine
Biovitrum
Bausch Health
EUSA Pharma
Camurus
Mission Pharmacal
Clinigen Group
Midatech Pharma
Alliance Pharma
AMAG Pharmaceuticals